Physician profile
Nathan Fox
NPI 1225050941
$4,782.67
in general payments reported to CMS, 2019-2025
13 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $4,047 · 2023: $170 · 2024: $92.97 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cytyc Prenatal Products Corp. | $4,000.00 | 2021 | |
| Biogen, INC. | $186.01 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $153.44 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Ge Healthcare | $99.82 | 2023 | |
| Exeltis, USA INC. | $80.15 | 2021-2025 | Slynd |
| Shield Therapeutics INC | $60.04 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $56.98 | 2025 | Veozah |
| Duchesnay USA Incorporated | $35.29 | 2019 | |
| Mission Pharmacal Company | $32.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.16 | 2023 | |
| Covidien Lp | $22.99 | 2019 | |
| Therapeuticsmd, INC. | $16.11 | 2019 | |
| Celularity INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.